Resumption of clinical trials of the AstraZeneca anti-COVID-19 vaccine in Brazil

<p style=";text-align:left;direction:ltr"> <strong>ArabiaWeather</strong> - Astra Zeneca in Brazil Monday resumed clinical trials of its vaccine anti-virus Corona in Brazil, which was developed by the company in collaboration with the University of Oxford, after the organization for health affairs body in the country to confirm the resumption of its British counterpart test. </p><p style=";text-align:left;direction:ltr"></p><p style=";text-align:left;direction:ltr"> The Federal University of Sao Paulo, which is conducting the experiments, said in a statement that it had given the vaccine to 4,600 out of 5,000 volunteers in Brazil, without any of them reporting any serious health problems. </p><p style=";text-align:left;direction:ltr"></p><p style=";text-align:left;direction:ltr"> The experiments involved volunteers from Sao Paulo, Rio de Janeiro and Salvador in the northeastern state of Bahia. </p><p style=";text-align:left;direction:ltr"></p><p style=";text-align:left;direction:ltr"> It is noteworthy that AstraZeneca had temporarily suspended global trials last week after an unexplained illness of one of the participants in Britain. </p><p style=";text-align:left;direction:ltr"></p><p style=";text-align:left;direction:ltr"> Brazil is suffering from the third worst outbreak of the Corona virus after the United States and India, and it has become an attractive ground for testing anti-Covid-19 vaccines developed by Britain, China and Russia. </p><p style=";text-align:left;direction:ltr"></p><p style=";text-align:left;direction:ltr"> <strong>Source: Reuters</strong> </p>